These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

710 related items for PubMed ID: 17313377

  • 1. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N.
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [Abstract] [Full Text] [Related]

  • 7. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K, Bock O, Kreipe H.
    Pathobiology; 2007 Apr; 74(2):72-80. PubMed ID: 17587878
    [Abstract] [Full Text] [Related]

  • 8. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL, Marton E, Plander M.
    Orv Hetil; 2011 Nov 06; 152(45):1795-803. PubMed ID: 22011365
    [Abstract] [Full Text] [Related]

  • 9. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
    Musolino C, Allegra A, Penna G, Centorrino R, Cuzzola M, D'Angelo A, Iacopino P, Alonci A.
    Acta Haematol; 2009 Nov 06; 122(1):46-9. PubMed ID: 19816006
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
    Larsen TS, Hasselbalch HC, Pallisgaard N, Kerndrup GB.
    Cancer Genet Cytogenet; 2007 Jan 15; 172(2):107-12. PubMed ID: 17213018
    [Abstract] [Full Text] [Related]

  • 14. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May 15; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M, Le Guellec S, Quelen C, Rigal-Huguet F, Delsol G, Brousset P.
    Hum Pathol; 2006 Nov 15; 37(11):1458-64. PubMed ID: 16949922
    [Abstract] [Full Text] [Related]

  • 19. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Nov 15; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 20. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
    Najfeld V, Cozza A, Berkofsy-Fessler W, Prchal J, Scalise A.
    Exp Hematol; 2007 Nov 15; 35(11):1668-76. PubMed ID: 17976519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.